Amrubicin
(Synonyms: 氨柔比星,SM-5887) 目录号 : GC15644
Amrubicin (SM-5887) 是一种 DNA 拓扑异构酶 II 抑制剂，用于癌症研究。
Cas No.:110267-81-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
A synthetic anthracycline antibiotic. It inhibits DNA topoisomerase II. Antineoplastic.
| Cell experiment: [1] | |
|
Cell lines |
CCRF-CEM cells |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
IC 50: 3.3 µM, 1 hour |
|
Applications |
Amrubicin induced DNA-protein complex formation in cultured CCRF-CEM cells in a dose-dependent manner. The IC50 value of amrubicin required to inhibit the growth of CCRF-CEM cells was 3.3 µM. Accordingly, under conditions where cell growth was inhibited by amrubicin, considerable amounts of DNA-protein complexes were formed. |
| Animal experiment: [2] | |
|
Animal models |
BALB/c nu/nu mice bearing Lu-24 or Lu-134 cells |
|
Dosage form |
Intravenous injection, 25 mg/kg |
|
Applications |
Amrubicin showed significant antitumor activities against both SCLC tumors tested, Lu-24 and Lu-134, with T/C-values at day 14 of 17% and 9%, respectively. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Hanada M, Mizuno S, Fukushima A, et al. A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II-DNA Complex. Cancer Science, 1998, 89(11): 1229-1238. [2] Hanada M, Noguchi T, Yamaoka T. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo. Cancer science, 2007, 98(3): 447-454. | |
| Cas No. | 110267-81-7 | SDF | |
| 别名 | 氨柔比星,SM-5887 | ||
| 化学名 | (7S,9S)-9-acetyl-9-amino-7-[(2S,4S,5R)-4,5-dihydroxyoxan-2-yl]oxy-6,11-dihydroxy-8,10-dihydro-7H-tetracene-5,12-dione | ||
| Canonical SMILES | CC(=O)C1(CC(C2=C(C3=C(C(=C2C1)O)C(=O)C4=CC=CC=C4C3=O)O)OC5CC(C(CO5)O)O)N | ||
| 分子式 | C25H25NO9 | 分子量 | 483.47 |
| 溶解度 | ≥ 16.45mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0684 mL | 10.3419 mL | 20.6838 mL |
| 5 mM | 0.4137 mL | 2.0684 mL | 4.1368 mL |
| 10 mM | 0.2068 mL | 1.0342 mL | 2.0684 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet